Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candid...See more
Headquarter Australia |
Countries of operation Australia |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Vice President Clinical Development
Senior Associate, Clinical Development
Senior Research Assistant
Share capital injection/new funding: approx. USD 70,000,000